Anxiety and depression in patients with epilepsy during the COVID-19 pandemic assessed with HADS-scale
Abstract number :
1.389
Submission category :
Camelice Poster
Year :
2021
Submission ID :
1886409
Source :
www.aesnet.org
Presentation date :
12/4/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:56 AM
Authors :
E. Rodrigo Velasquez Coria, MD - National Institute of Neurology and Neurosurgery; Karen Guzman, MD – Fellow, Epilepsy, National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Elizabet Ruiz, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Manuel Del Rio-Quiñones, PhD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Jimena Armenta, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Kevin Enriquez, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Emilia González, MD – Epilepsy – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Aurelio Jara, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Jorge López, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Salvador Martínez, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Adriana Ochoa, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Karla Rodríguez, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Andrea Santos, MD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Mario A. Sebastian-Diaz, PhD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Arnold Thomson, MD – Epilepsy – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Daniel Crail, PhD – National Institute of Neurology and Neurosurgery Manuel Velasco Suarez; Iris E. Martínez-Juarez, PhD – Director, Epilepsy, National Institute of Neurology and Neurosurgery Manuel Velasco Suarez
Rationale: Describe the prevalence of anxiety and depression measured by the HADS-scale in patients diagnosed with epilepsy assessed in telemedicine and face-to-face consultation in 2020 during the onset of the COVID-19 pandemic in Mexico.
Methods: Prospective, observational, descriptive study in patients with epilepsy from the NINN “MVS” Epilepsy Clinic during 2020. After informed consent, HADS scale was applied, taking the value of 7 as the cut-off point for diagnosis. Percentages and frequencies were used for qualitative variables. For the quantitative variables, means were used.
Results: A total sample of 110 patients was obtained. In the HADS-A scale, 55 (50%) patients with anxiety were found with an average of 6 points. On the HADS-D scale, 34 (31%) patients with depression were found with an average of 4 points. Anxiety symptoms found most frequently was the one that corresponded to those who reported “having the head full of worries” found in 87 (79%) patients. The most frequent symptom of depression was found in 69 (63%) patients who reported “feeling sluggish and clumsy.”
Conclusions: Comparing with a previous study performed at NINN1, it could be concluded that during the onset of COVID-19 pandemic there was an increase of the incidence of anxiety to 5% and 11% in depression in patients with epilepsy attended by teleconsultation and in person. These data are consistent with the expected phenomenon in the fourth wave of the COVID-19 pandemic.
Funding: Please list any funding that was received in support of this abstract.: No Funding in this work.
Camelice Poster